

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

## **PROFIT WARNING**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, the preliminary assessment pursuant to of the unaudited consolidated financial statements of the Group and other currently available information is as follows:

The Group has overcome the adverse impacts such as the recurrence of the COVID-19 pandemic and achieved an increase of approximately 16% in revenue year-on-year for the year ended 31 December 2022 (the “**Reporting Period**”) (excluding the effect of exchange rates on such revenue growth rate and the revenue growth rates shown in this announcement). Such increase was principally attributable to:

- (i) Driven by the launching of new products and market promotion, the listed subsidiaries achieved rapid growth in sales revenue. Among which, revenue from EV MedTech\* (endovascular and peripheral vascular devices business) grew by approximately 31% year-on-year, revenue from MicroPort NeuroTech\* (neurovascular business) grew by over 40% year-on-year, revenue from CardioFlow Medtech\* (heart valve business) grew by approximately 25% year-on-year, and revenue from MicroPort MedBot\* (surgical robot business) also achieved a year-on-year growth of over 850%;
- (ii) revenue from other major businesses within the Group grew steadily. Among which, revenue from the orthopedic devices business, the cardiac rhythm management business and cardiovascular devices business increased by approximately 9%, 5% and 2% year-on-year, respectively; and
- (iii) exponential growth in revenue from emerging businesses.

\* *EV MedTech, MicroPort NeuroTech, CardioFlow Medtech and MicroPort MedBot refer to the Group’s subsidiaries that have been separately listed*

During the Reporting Period, the Group recorded losses of less than USD585 million (as compared to losses for the corresponding period last year of approximately USD351.3 million). The change was principally attributable to:

- (i) the increase in one off and/(or) non-cash provisions and losses increased by approximately USD105 million to USD120 million, including the increase in accrued interest on convertible bonds issued by the Group and preference shares issued by subsidiaries, the increase in loss on fair value changes and provisions for impairment of certain non-current assets, and the increase in share of losses of equity-accounted investees;
- (ii) the increase in costs of actively pursuing research and development, registration and commercialisation of separately listed subsidiaries MicroPot MedBot\* and CardioFlow Medtech\*;
- (iii) the increase in research and development investment, clinical registration and market expansion in overseas markets of the other major businesses within the Group.

As at the date of this announcement, the Company is still in the process of preparing and completing the annual results of the Group for the year ended 31 December 2022 (the “**2022 Annual Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the Company’s shares and securities and potential investors are advised to read the Company’s announcement for the 2022 Annual Results carefully, which is expected to be published by the end of March 2023. Holders of the Company’s shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 28 February 2023

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *For identification purpose only*